Faculty, Staff and Student Publications
Publication Date
8-1-2023
Journal
The Journal for ImmunoTherapy of Cancer
DOI
10.36401/JIPO-22-33
PMID
37637237
PMCID
PMC10448731
PubMedCentral® Posted Date
6-28-2023
PubMedCentral® Full Text Version
Post-print
Abstract
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.
Keywords
brain metastasis, breast cancer, ataxia-telangiectasia mutation (ATM), PARPi, precision medicine
Published Open-Access
yes
Recommended Citation
Chelariu-Raicu, Anca; Piha-Paul, Sarina A; Chavez-MacGregor, Mariana; et al., "Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation" (2023). Faculty, Staff and Student Publications. 3389.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/3389
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons